About
Multiple Myeloma is a cancer characterized by the proliferation of a clone of plasma cells in the bone marrow and induces overproduction of immunoglobulins (antibody proteins) that crowd out the normal blood-forming cells and prevent them from functioning effectively.
The symptoms of Multiple Myeloma include bone lesions, anaemia, kidney damage and susceptibility to infections. Patients commonly experience bone pain and fractures, also experiencing weight loss, tiredness and repeated infections(2).
The tumor plasma cell clone proliferation induces high level concentration of Monoclonal protein (also called M-Protein) which is the best tumor markers of the disease.
Diagnosis
Serum and urine protein electrophoresis and their immunological characterization are the gold standard for Multiple Myeloma diagnosis, for monitoring the disease and to assess the patient’s response to treatment.
Protein electrophoresis is recommended by IMWG (International Myeloma Working Group) for screening serum and urine samples for protein abnormality detection(3).
Once the Monoclonal protein is identified (or suspected), it must be characterized by an immunofixation or immunotyping test to identify the M-Protein type (IgG, IgA, IgM, IgD, IgE) and light chain (kappa or Lambda) involved.
Sebia's Expertise
Sebia is the world leader in diagnosis and monitoring of Multiple Myeloma patients by offering a full range of solutions to enable clinicians to provide optimal medical care. Ensuring high quality results adapted to all laboratory sizes. Sebia solutions offer serum and urine proteins electrophoresis (SPE/UPE) for screening and identification (immunofixation/Immunotyping) and follow-up monoclonal antibody therapy with HYDRASHIFT portfolio.
Featured resources on Multiple Myeloma
See all resourcesHYDRASHIFT avoids monoclonal antibody interference on IMMUNOFIXATION
The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with daratumumab.
Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab
Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.
Multiple Myeloma clinical cases for diagnosis and monitoring according to latest IMWG recommendations
Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD
Performance of Immunotyping vs. Immunofixation for the Detection of Monoclonal Gammopathies
Educational Webinar with Katie Thoren, PhD, Memorial Sloan Kettering Cancer Center
AL Amyloidosis: Role of clinical lab in diagnosis and management
Educational Webinar with Prof. Giovanni PALLADINI, PhD
Moving from IF to Immunotyping Testing to Increase Productivity and Reduce Errors in M-protein Identification
Learn how a Sebia customer utilized our Workflow Service offering and CAPILLARYS 3 instruments to achieved higher throughput and improved workflow.
Early detection of Multiple Myeloma: The importance of serum protein electrophoresis
Educational Webinar with Dr. Julien GUILLEMAUD
Moving from Immunofixation to Immunotyping Improves Standard of Care by Hand-on and Turnaround Time
Learn how a Sebia customer gained both clinically and operationally with a simplified IT workflow.
Challenges in Implementing Capillary Electrophoresis for Immunotyping
Educational Webinar with Dr. Jack Maggiore from Loyola University Medical Center in Chicago, IL
Sebia USA Learning Series
Sebia specializes in providing testing solutions for a range of diseases, including Diabetes and Multiple Myeloma. Learn about the impact of these diseases and the medical solutions available.
HYDRASYS 2 SCAN FOCUSING: Overview
Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.
Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Complete your Myeloma diagnostic tools with Sebia FLC Assay
The serum Free Light Chains is an important test in the diagnosis and monitoring of Multiple Myeloma patients.
Upcoming events
See all events
CAPILLARYS 3 OCTA
Evolution makes the difference.
CAPILLARYS 3 TERA MC
Capillary Electrophoresis solution to meet your high capacity needs.
MINICAP FLEX-PIERCING
The compact and affordable automation of Capillary Electrophoresis.
HYDRASYS 2 SCAN FOCUSING
Large menu with high quality results on gel electrophoresis.
Serum Protein by Capillary Electrophoresis
High throughput Serum Protein Electrophoresis with high resolution results.
Urine Protein by Agarose Gel Electrophoresis
Proteinuria screening for renal disease.
Urine Protein by Capillary Electrophoresis
High throughput Urine Protein Electrophoresis, with high resolution results.
Serum and Urine Immunofixation
Identification of monoclonal proteins by agarose gel electrophoresis.
Serum and Urine Immunotyping
Fully automated monoclonal proteins identification by Capillarys electrophoresis.
(1) https://www.cancerresearchuk.org
(2) https://www.mayoclinic.org/
(3) https://www.myeloma.org/international-myeloma-working-group
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.